Akso Health granted additional 180-day compliance period by Nasdaq

Akso Health Group has received a notification letter from the Nasdaq Stock Market on April 25, 2023, notifying the Company that it has been granted an additional 180-day compliance period, or until October 23, 2023 to regain compliance with Nasdaq’s minimum bid price rule. Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period and if necessary, by effecting a reverse share split. Previously, in a notification letter dated October 26, 2022, Nasdaq had notified the Company that, based on the previous 30 consecutive business days, the Company’s ADSs no longer met the minimum $1 bid price per share requirement. Therefore, in accordance with Nasdaq’s Listing Rules, the Company was provided 180 calendar days, or until April 24, 2023, to regain compliance. If at any time before October 23, 2023, the closing bid price of the Company’s ADSs is at least $1 per ADS for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed. This current notification from Nasdaq has no immediate effect on the listing or trading of the Company’s ADSs, which will continue to trade on the Nasdaq Capital Market under the symbol "AHG". The Company will actively monitor the closing bid price of its ADSs between now and October 23, 2023 and intends to consider all available options to resolve the deficiency and regain compliance within the additional compliance period provided.